Amylyx Pharmaceuticals, Inc.
AMLX
Peringkat dalam Saham
#4313
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Harga Saham
$28.83
Kapitalisasi Pasar
$3.62B
Perubahan (1 hari)
5.49%
Perubahan (1 tahun)
87.57%
Negara
US
Perdagangan Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
Rasio P/B untuk Amylyx Pharmaceuticals, Inc. (AMLX)
Rasio P/B per October 2026 TTM: 12.57
Menurut laporan keuangan dan harga saham terbaru dari Amylyx Pharmaceuticals, Inc., rasio P/B saat ini (TTM) adalah 12.57. Pada akhir 2023, rasio P/B perusahaan adalah 2.28.
Riwayat rasio P/B untuk Amylyx Pharmaceuticals, Inc. dari 2019 hingga 2026
Rasio P/B pada akhir setiap tahun
| Tahun | Rasio P/B | Mengubah |
|---|---|---|
| 2026 (TTM) | 12.57 | 705.59% |
| 2024 | 1.56 | -31.54% |
| 2023 | 2.28 | -68.35% |
| 2022 | 7.22 | -204.32% |
| 2021 | -6.92 | -54.77% |
| 2020 | -15.29 | -62.00% |
| 2019 | -40.24 | 0.00% |
Rasio P/B untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/B | Perbedaan Rasio P/B | Negara |
|---|---|---|---|
| 6.251 | -50.26% |
US
|
|
| 13.2547 | 5.47% |
US
|
|
| 4.208 | -66.52% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -50.81% |
NL
|
